by Nigel Rawson
November 07, 2013
Slow regulatory and reimbursement approvals in Canada are affecting cancer survival. More than 5,000 patients could have been negatively affected by delayed federal regulatory and provincial reimbursement approval of five new oncology drugs. Patients affected by slow regulatory and reimbursement approval procedures are anonymous and receive less attention from decision-makers than victims of adverse drug reactions. This study identifies a substantial number of real people who should not be ignored.